"Is this peptide legal?" has three different answers depending on the path: (1) FDA-approved drug — a real medicine you can be prescribed; (2) compounded — made for you by a pharmacy under Section 503A/503B rules; or (3) research chemical — sold online "not for human use," outside the approved system entirely.
In April 2026 the FDA removed 12 popular peptides (including BPC-157 and TB-500) from its 503A "Category 2" safety-concern list — but did not approve them. They're in limbo pending a Pharmacy Compounding Advisory Committee (PCAC) review on July 23–24, 2026 and the formal rulemaking that would follow.
Separately, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, closing the mass-compounding pathway for those GLP-1s. Through all of it, products sold as "research chemicals" remain outside the legal framework — nothing in 2026 changed that.
→ For how to vet any product or COA, see the Trust & Verification hub. For the deeper legal picture, see Are Peptides Legal?
The framework: three questions, not one
Most confusion about peptide legality comes from collapsing three separate questions into one. Keep them apart:
1. Is it an FDA-approved drug? If yes, it's a normal prescription medicine (e.g., semaglutide, tirzepatide). This is the only path where identity, dose, and sterility are guaranteed.
2. Can a pharmacy compound it? Compounding is governed by two sections of federal law. Section 503A covers patient-specific compounding by a pharmacy for an individual prescription. Section 503B covers larger "outsourcing facilities" that compound from bulk. Each maintains a list of bulk substances sorted into categories:
- Category 1 — under evaluation, no significant safety concerns identified; compounding is generally permitted under interim enforcement discretion.
- Category 2 — significant safety concerns identified; compounding is not permitted.
- Category 3 — nomination lacked sufficient information to evaluate.
3. Is it just a "research chemical"? Most peptides sold online fall here — marketed "for research use only / not for human consumption." This framing is a legal gray area that has been collapsing under enforcement, and it sits entirely outside the approval and compounding systems above.
A critical nuance the hype sites gloss over: removal from Category 2 is not the same as approval, and not the same as Category 1. A substance can be off the "do not compound" list and still not be legal to compound — which is exactly where a dozen peptides sit right now.
Status table: where major peptides stand
Grouped by regulatory path. "Compounding" reflects 503A status as of the last-verified date. This is a snapshot of a fast-moving picture — always confirm current status before relying on it.
✅ FDA-approved medicines
| Peptide / drug | Brand(s) | Status |
|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Approved (T2D, obesity) |
| Tirzepatide | Mounjaro, Zepbound | Approved (T2D, obesity) |
| Liraglutide | Victoza, Saxenda | Approved (T2D, obesity) |
| Dulaglutide | Trulicity | Approved (T2D) |
| Somatropin | multiple | Approved (growth hormone) |
| Teriparatide | Forteo | Approved (osteoporosis) |
| Orforglipron | Foundayo | Approved Apr 2026 — note: a small molecule, not a peptide |
🧪 Investigational (in trials, not approved)
| Peptide | Stage | Notes |
|---|---|---|
| Retatrutide | Phase 3 (TRIUMPH) | Approval realistically 2027–2028 — see the status tracker |
| CagriSema | Phase 3 | GLP-1 + amylin combination |
| Survodutide | Phase 3 | GLP-1 + glucagon dual agonist |
⚠️ Removed from Category 2 in April 2026 — now in limbo
Not approved, not on Category 1, not (yet) legally compoundable. Under PCAC review (see schedule below). Widely sold as research chemicals, which remains outside the approved framework.
| Peptide | Compounding status | PCAC review |
|---|---|---|
| BPC-157 | Limbo (off Cat 2, not Cat 1) | Jul 23, 2026 |
| TB-500 | Limbo | Jul 23, 2026 |
| MOTS-c | Limbo | Jul 23, 2026 |
| KPV | Limbo | Jul 23, 2026 |
| Emideltide (DSIP) | Limbo | Jul 24, 2026 |
| Semax | Limbo | Jul 24, 2026 |
| Epitalon | Limbo | Jul 24, 2026 |
| GHK-Cu (injectable) | Limbo (route-specific) | By end of Feb 2027 |
| Melanotan II | Limbo | By end of Feb 2027 |
| Cathelicidin (LL-37) | Limbo | By end of Feb 2027 |
| Dihexa | Limbo | By end of Feb 2027 |
| PEG-MGF | Limbo | By end of Feb 2027 |
All twelve were removed because their original nominations were withdrawn — not because the FDA cleared them. Several are reviewed in both free-base and acetate salt forms.
The July 2026 PCAC schedule
The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on whether a bulk substance should be added to the 503A bulks list. It is meeting July 23–24, 2026, to consider the first seven peptides, with five more slated before the end of February 2027.
| Date | Peptides under review |
|---|---|
| July 23, 2026 | BPC-157, KPV, TB-500, MOTS-c (free base + acetate forms) |
| July 24, 2026 | Emideltide (DSIP), Semax, Epitalon |
| By end of Feb 2027 | GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa, PEG-MGF |
Three things to keep in perspective. First, a PCAC recommendation is non-binding, and even a favorable vote must go through formal notice-and-comment rulemaking that can take more than a year. Second, when the PCAC last reviewed peptides in 2024, it recommended against adding all of them, citing safety risks — so a different outcome is possible but not guaranteed. Third, the committee has had vacancies and quorum questions that could affect the meeting. In short: July is a milestone, not a finish line. Public comments were open ahead of the meeting (written comments by early July to reach the committee directly).
→ Our news desk covered the announcement: FDA pulls 12 peptides off its "do not compound" list.
The GLP-1 compounding situation
GLP-1s are a separate story because they're already approved drugs. During the semaglutide and tirzepatide shortages, compounding pharmacies were permitted to make copies; once the FDA declared the shortages resolved (semaglutide in February 2025), that allowance began closing. Then, on April 30, 2026, the FDA proposed a rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — removing the mass-compounding pathway regardless of any future shortage.
What it doesn't change, at least yet: patient-specific 503A compounding can still occur where a prescriber documents a specific clinical need for an individual patient, within the FDA's "essentially a copy" limits (the agency has signaled it doesn't intend to act against 503A pharmacies filling roughly four or fewer such prescriptions per month). The direction of travel, though, is clear — toward the approved branded products and away from compounded GLP-1s.
→ Full breakdown: The FDA just proposed ending mass GLP-1 compounding.
Approval pipeline
| Compound | Indication | Realistic timeline |
|---|---|---|
| Orforglipron (Foundayo) | Obesity (oral) | ✅ Approved April 2026 |
| Retatrutide | Obesity, T2D | NDA ~late 2026; decision ~2027–2028 |
| CagriSema | Obesity | Phase 3 ongoing |
| Survodutide | Obesity, MASH | Phase 3 ongoing |
| Oral semaglutide (obesity) | Obesity | ✅ Approved (oral Wegovy, Jan 2025) |
What this means in practice
Cutting through it: if you want a peptide medicine with guaranteed identity, dose, and sterility, the only clear path is an FDA-approved product prescribed by a clinician. For the dozen peptides in limbo, compounding through a licensed 503A pharmacy may become clearer after the PCAC process — but as of now their status is legally uncertain, and that's a conversation for a prescriber and pharmacist, not a checkout button. "Research chemical" purchases remain outside the approved framework entirely; nothing in the 2026 changes altered that. This tracker is a map of the rules, not legal advice — when stakes are real, consult a qualified professional.
Change log
So you can see what moved and when (newest first):
| Date | Change |
|---|---|
| May 19, 2026 | Tracker published. Status current as of this date. |
| Apr 30, 2026 | FDA proposed permanent 503B bulks exclusion for semaglutide, tirzepatide, liraglutide. |
| Apr 22, 2026 | 12 peptides formally removed from 503A Category 2 (effective date). |
| Apr 15–16, 2026 | FDA announced the Category 2 removals and scheduled PCAC for July 23–24, 2026. |
| Apr 1, 2026 | Orforglipron (Foundayo) approved by the FDA. |
| Feb 2025 | FDA declared the semaglutide shortage resolved, beginning the close of GLP-1 compounding. |
| Late 2023 | FDA placed 19 peptides into 503A Category 2. |
Spot something out of date? This is a living document — email editors@greypeptides.com and we'll verify and update.
Frequently asked questions
Is BPC-157 legal now?
It's not FDA approved and has no USP monograph. It was removed from Category 2 in April 2026 (nomination withdrawn) but not placed on Category 1, so it's in a gray zone pending the July 23, 2026 PCAC review. Research-chemical versions remain outside the approved framework.
What's the difference between 503A and 503B?
503A is patient-specific compounding by a pharmacy for one prescription; 503B is bulk compounding by larger outsourcing facilities. They have separate bulk-substance rules. The April 2026 GLP-1 exclusion targets the 503B bulks list.
If a peptide left Category 2, can my pharmacy make it?
Not automatically. Removal from Category 2 only lifts the "significant safety concerns" label; it doesn't authorize compounding. That requires Category 1 placement via PCAC review and rulemaking.
Are research-chemical peptides legal to use?
They're sold "not for human consumption," are not approved, and are not lawful for compounding. Using them is outside the approved system, and recent enforcement has targeted sellers who cross into human-use marketing.
Related on Grey Peptides
Hubs & guides
From the News Wire
FDA pulls 12 peptides off its "do not compound" list → FDA proposes ending mass GLP-1 compounding →Get regulatory updates
We update this tracker whenever the FDA, PCAC, or DOJ moves. No spam, unsubscribe anytime.
Sources
Drawn from FDA primary documents and contemporaneous regulatory/legal reporting. Status reflects the last-verified date above and can change.
- U.S. FDA — Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A; 503A interim bulks list (Categories 1–3), updated April 15, 2026.
- U.S. FDA — Federal Register notice and advisory-committee calendar for the Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026.
- U.S. FDA — proposed rule on 503B bulks list and GLP-1 compounding, April 30, 2026.
- FDA drug approvals (semaglutide, tirzepatide, liraglutide, orforglipron) and Eli Lilly / Novo Nordisk regulatory communications.
- Contemporaneous regulatory-law analysis (e.g., Frier Levitt, Orrick, National Law Review, FDA Law Blog) on the April 2026 peptide category changes.
Educational only — not legal or medical advice. Regulatory status changes frequently; verify current status with primary sources and a qualified professional before relying on it.